Home
Data
Calendar
Blog
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock Value | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | NA | NA | NA | NA | NA | |
| Weighted Average Number Of Diluted Shares Outstanding | 52.07 | NA | 51.18 | 50.97 | 43.47 | NA | 38.57 | 38.38 | 26.75 | NA | 23.37 | 23.37 | NA | NA | NA | |
| Weighted Average Number Of Shares Outstanding Basic | 52.07 | NA | 51.18 | 50.97 | 43.47 | NA | 38.57 | 38.38 | 26.75 | NA | 23.37 | 23.37 | NA | NA | NA | |
| Earnings Per Share Basic | -1.01 | -1.11 | -1.40 | -0.83 | -1.08 | -0.46 | -1.76 | -2.02 | -3.20 | -2.54 | -2.57 | -3.60 | -3.73 | NA | NA | |
| Earnings Per Share Diluted | -1.01 | -1.11 | -1.40 | -0.83 | -1.08 | -0.46 | -1.76 | -2.02 | -3.20 | -2.54 | -2.57 | -3.60 | -3.73 | NA | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 12.44 | 10.68 | 12.03 | 36.05 | 41.62 | 56.18 | 13.41 | 13.48 | 8.43 | 16.03 | 19.26 | 7.33 | 11.90 | 9.90 | 18.43 | |
| Cost Of Goods And Services Sold | NA | 0.00 | 0.55 | 0.91 | 0.64 | 0.47 | 0.38 | 0.36 | 0.51 | 0.41 | 0.32 | 0.09 | 1.70 | 1.50 | 1.32 | |
| Costs And Expenses | 63.59 | 70.62 | 90.00 | 84.04 | 93.33 | 83.39 | 81.78 | 90.45 | 99.02 | 84.41 | 84.50 | 95.30 | 104.27 | 91.45 | 94.85 | |
| Research And Development Expense | 43.93 | 51.22 | 51.31 | 59.98 | 68.25 | 49.31 | 61.74 | 68.44 | 69.25 | 59.54 | 61.13 | 63.69 | 77.57 | 68.88 | 72.25 | |
| Selling General And Administrative Expense | 12.66 | 16.20 | 13.00 | 19.49 | 20.72 | 18.70 | 19.61 | 17.28 | 23.86 | 24.48 | 23.00 | 21.40 | 24.63 | 21.95 | 22.11 | |
| Operating Income Loss | -51.15 | -59.94 | -77.97 | -47.99 | -51.71 | -27.21 | -68.37 | -76.97 | -90.59 | -68.37 | -65.24 | -87.97 | -92.37 | -81.55 | -76.41 | |
| Interest Income Expense Nonoperating Net | 2.86 | 3.65 | 3.63 | 3.09 | 2.05 | 1.49 | 1.11 | 0.21 | 0.12 | NA | NA | NA | NA | NA | NA | |
| Allocated Share Based Compensation Expense | 4.68 | 4.99 | 9.80 | 7.74 | 9.67 | 9.37 | 12.21 | 9.69 | 9.74 | 14.29 | 11.23 | 11.97 | 17.11 | 12.44 | 15.26 | |
| Other Comprehensive Income Loss Net Of Tax | -0.13 | NA | 0.51 | 0.52 | 0.93 | NA | -0.50 | -0.58 | -2.09 | NA | NA | NA | NA | NA | NA | |
| Net Income Loss | -52.67 | -56.82 | -71.64 | -42.09 | -47.02 | -23.14 | -67.88 | -77.42 | -85.71 | -60.98 | -60.00 | -84.04 | -87.20 | -76.80 | -72.08 | |
| Comprehensive Income Net Of Tax | -52.80 | -56.11 | -71.12 | -41.57 | -46.09 | -22.13 | -68.38 | -78.00 | -87.80 | -61.69 | -60.00 | -84.04 | -87.20 | NA | NA | |
| Goodwill Impairment Loss | NA | 0.00 | 12.06 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | 511.05 | 565.43 | 640.81 | 705.71 | 742.44 | 656.66 | 708.74 | 787.41 | 851.92 | 759.67 | 192.96 | NA | NA | 312.62 | NA | |
| Liabilities | 303.61 | 310.13 | 334.38 | 338.22 | 341.11 | 346.20 | 385.56 | 408.42 | 404.50 | 399.85 | 251.37 | NA | NA | 237.99 | NA | |
| Liabilities And Stockholders Equity | 511.05 | 565.43 | 640.81 | 705.71 | 742.44 | 656.66 | 708.74 | 787.41 | 851.92 | 759.67 | 192.96 | NA | NA | 312.62 | NA | |
| Stockholders Equity | 207.44 | 255.30 | 306.42 | 367.50 | 401.32 | 310.47 | 323.18 | 378.98 | 447.42 | 359.82 | -58.41 | 48.69 | 75.64 | 74.63 | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets Current | 212.84 | 237.76 | 277.25 | 333.67 | 389.82 | 300.88 | 349.42 | 383.89 | 412.80 | 291.56 | 24.59 | NA | NA | 25.10 | NA | |
| Cash And Cash Equivalents At Carrying Value | 56.79 | 74.96 | 90.23 | 95.99 | 193.63 | 71.03 | 127.02 | 269.87 | 270.89 | 130.41 | NA | NA | NA | NA | NA | |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 57.02 | 76.68 | 92.14 | 97.67 | 195.08 | 104.06 | 159.84 | 302.88 | 304.05 | 163.27 | NA | NA | NA | NA | NA | |
| Receivables Net Current | 11.98 | 13.41 | 19.52 | 44.10 | 41.25 | 20.96 | 12.04 | 12.16 | 16.93 | 17.00 | 16.14 | NA | NA | 10.69 | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Property Plant And Equipment Gross | 64.86 | 115.06 | 114.74 | 113.00 | 109.07 | 103.57 | 92.34 | 82.69 | 76.63 | 74.99 | 71.43 | NA | NA | 174.06 | NA | |
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | 26.62 | 56.91 | 54.06 | 51.98 | 49.91 | 47.84 | 45.69 | 43.49 | 41.59 | 40.08 | 37.68 | NA | NA | 30.04 | NA | |
| Property Plant And Equipment Net | 38.23 | 58.15 | 60.68 | 61.02 | 59.15 | 55.73 | 46.65 | 39.20 | 35.04 | 34.91 | 33.75 | NA | NA | 144.03 | NA | |
| Intangible Assets Net Excluding Goodwill | 6.42 | 6.59 | 6.77 | 6.95 | 7.12 | 7.30 | 7.48 | 7.66 | 8.77 | 9.89 | 11.01 | NA | NA | 5.64 | NA | |
| Finite Lived Intangible Assets Net | NA | 6.59 | NA | NA | NA | 7.30 | NA | NA | NA | 9.89 | NA | NA | NA | 5.64 | NA | |
| Available For Sale Debt Securities Amortized Cost Basis | 124.65 | 146.75 | 194.38 | 211.21 | 148.83 | 198.75 | 200.40 | 131.29 | 183.82 | 232.33 | NA | NA | NA | NA | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities Current | 60.41 | 59.78 | 68.01 | 66.89 | 76.93 | 79.79 | 79.90 | 99.01 | 106.31 | 98.39 | 106.08 | NA | NA | 75.87 | NA | |
| Accounts Payable Current | 8.80 | 6.03 | 5.31 | 6.27 | 13.40 | 7.21 | 7.98 | 6.68 | 13.65 | 6.02 | 6.20 | NA | NA | 7.15 | NA | |
| Other Accrued Liabilities Current | 3.96 | 2.63 | 2.56 | 3.43 | 3.23 | 3.42 | 5.54 | 4.67 | 8.35 | 7.91 | 11.23 | NA | NA | 3.91 | NA | |
| Contract With Customer Liability Current | 16.34 | 15.40 | 13.03 | 12.64 | 8.48 | 3.00 | NA | NA | 5.00 | 5.00 | NA | NA | NA | 0.82 | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Other Liabilities Noncurrent | 0.69 | 2.42 | 2.41 | 2.40 | 2.40 | 2.40 | 2.42 | 2.45 | 2.43 | 2.12 | 2.94 | NA | NA | 2.49 | NA | |
| Operating Lease Liability Noncurrent | 240.07 | 244.01 | 247.89 | 251.71 | 255.47 | 259.01 | 262.49 | 265.91 | 269.29 | 272.45 | 99.82 | NA | NA | 112.29 | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | 207.44 | 255.30 | 306.42 | 367.50 | 401.32 | 310.47 | 323.18 | 378.98 | 447.42 | 359.82 | -58.41 | 48.69 | 75.64 | 74.63 | NA | |
| Common Stock Value | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | NA | NA | NA | NA | NA | |
| Additional Paid In Capital | 771.66 | 766.72 | 761.73 | 751.68 | 743.94 | 606.99 | 597.57 | 584.99 | 575.42 | 400.03 | NA | NA | NA | NA | NA | |
| Retained Earnings Accumulated Deficit | -563.89 | -511.22 | -454.39 | -382.76 | -340.67 | -293.65 | -270.50 | -202.62 | -125.20 | -39.49 | NA | NA | NA | NA | NA | |
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0.34 | -0.20 | -0.92 | -1.43 | -1.95 | -2.88 | -3.89 | -3.38 | -2.80 | -0.71 | NA | NA | NA | NA | NA | |
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | 4.68 | NA | 9.80 | 7.74 | 9.67 | NA | 12.21 | 9.69 | 9.74 | NA | 11.23 | 11.97 | 17.11 | NA | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -41.88 | -63.59 | -21.51 | -32.66 | -49.09 | -55.48 | -60.93 | -46.66 | -74.06 | -57.44 | -43.35 | -41.49 | -64.75 | -53.83 | NA | |
| Net Cash Provided By Used In Investing Activities | 21.83 | 47.89 | 16.05 | -64.88 | 44.80 | -0.53 | -82.29 | 49.77 | 44.75 | 34.01 | -8.62 | -3.62 | -6.35 | -7.00 | NA | |
| Net Cash Provided By Used In Financing Activities | 0.39 | 0.25 | -0.07 | 0.13 | 127.08 | 0.23 | 0.17 | -4.28 | 170.10 | 186.69 | 51.97 | 45.12 | 71.10 | 60.83 | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -41.88 | -63.59 | -21.51 | -32.66 | -49.09 | -55.48 | -60.93 | -46.66 | -74.06 | -57.44 | -43.35 | -41.49 | -64.75 | -53.83 | NA | |
| Net Income Loss | -52.67 | -56.82 | -71.64 | -42.09 | -47.02 | -23.14 | -67.88 | -77.42 | -85.71 | -60.98 | -60.00 | -84.04 | -87.20 | -76.80 | -72.08 | |
| Depreciation Depletion And Amortization | 2.11 | 3.03 | 2.76 | 2.24 | 2.25 | 2.33 | 2.38 | 3.30 | 3.53 | 3.54 | 4.67 | 4.47 | 3.68 | 3.32 | NA | |
| Increase Decrease In Accounts Payable | 3.25 | 0.59 | -0.52 | -7.57 | 7.07 | -0.10 | -0.69 | -5.12 | 6.23 | -0.61 | -6.55 | 2.62 | 4.54 | -1.89 | NA | |
| Share Based Compensation | 4.68 | 4.95 | 9.80 | 7.74 | 9.67 | 9.40 | 12.21 | 9.69 | 9.74 | 14.32 | 11.23 | 11.97 | 17.11 | 12.44 | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Investing Activities | 21.83 | 47.89 | 16.05 | -64.88 | 44.80 | -0.53 | -82.29 | 49.77 | 44.75 | 34.01 | -8.62 | -3.62 | -6.35 | -7.00 | NA | |
| Payments To Acquire Property Plant And Equipment | 0.61 | 1.07 | 2.74 | 3.97 | 6.08 | 3.17 | 13.42 | 2.67 | 3.58 | 0.97 | 2.62 | 1.62 | 6.35 | 7.00 | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Financing Activities | 0.39 | 0.25 | -0.07 | 0.13 | 127.08 | 0.23 | 0.17 | -4.28 | 170.10 | 186.69 | 51.97 | 45.12 | 71.10 | 60.83 | NA |
| 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 | 2020-09-30 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 12.44 | 10.68 | 12.03 | 36.05 | 41.62 | 56.18 | 13.41 | 13.48 | 8.43 | 16.03 | 19.26 | 7.33 | 11.90 | 9.90 | 18.43 | |
| Regeneron Pharmaceuticals Incorporation,MUC16, Regeneron Collaboration Agreement Amendment One | 4.00 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | |
| Bristol Myers Squibb, Non Us, License And Manufacturing Services, Ide Cel License And Manufacturing Services | 2.20 | 2.32 | 3.32 | 2.99 | 6.12 | 3.79 | 3.12 | 3.52 | 2.79 | 2.20 | 5.31 | 4.28 | 5.10 | 4.32 | 6.91 | |
| Novo Nordisk A S, Novo Collaboration And License Agreement | 1.50 | 1.06 | 1.10 | 1.90 | 1.70 | 1.60 | 1.50 | 2.10 | 1.30 | NA | NA | NA | NA | NA | NA | |
| Royalty And Other Revenue | NA | 0.00 | 1.23 | 1.99 | 1.42 | 1.12 | 0.86 | 0.78 | 0.89 | 0.80 | 0.61 | 0.34 | 6.20 | 3.99 | 3.50 | |
| Service | 7.72 | 3.35 | 4.95 | 5.02 | 10.83 | 41.13 | 4.64 | 5.67 | 4.05 | 3.84 | 6.31 | 5.31 | 5.92 | 4.72 | 12.51 |
